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Abstract: In this work, we designed and fabricated a multifunctional nanocomposite system that 
consists of chitosan, raspberry-like silver nanoparticles, and graphene oxide. The room temperature 
atmospheric pressure microplasma (RT-APM) process provides a rapid, facile, and environmen-
tally-friendly method for introducing silver nanoparticles into the composite system. Our compo-
site can achieve a pH controlled single and/or dual drug release. Under pH 7.4 for methyl blue 
loaded on chitosan, the drug release profile features a burst release during the first 10 h, followed 
by a more stabilized release of 70–80% after 40–50 h. For fluorescein sodium loaded on graphene 
oxide, the drug release only reached 45% towards the end of 240 h. When the composite acted as a 
dual drug release system, the interaction of fluorescein sodium and methyl blue slowed down the 
methyl blue release rate. Under pH 4, both single and dual drug systems showed a much higher 
release rate. In addition, our composite system demonstrated strong antibacterial abilities against 
E. coli and S. aureus, as well as an excellent photothermal conversion effect under irradiation of near 
infrared lasers. The photothermal conversion efficiency can be controlled by the laser power. These 
unique functionalities of our nanocomposite point to its potential application in multiple areas, such 
as multimodal therapeutics in healthcare, water treatment, and anti-microbials, among others. 
Keywords: chitosan; silver nanoparticles; graphene oxide; nanocomposites; antibacterial; drug de-
livery; photothermal conversion 
 
1. Introduction 
Chitosan (CS) exhibits biocompatibility and biodegradability, and has been explored 
widely for biomedical applications such as bone/skin regeneration, wound dressing, and 
cancer therapy [1–3]. Graphene oxide (GO), on the other hand, has excellent mechanical 
properties [4]. Its high specific surface area and oxygen-containing surface functional 
groups have enabled its application as a drug carrier [5,6]. In addition, GO has also 
emerged as a promising photothermal agent for photothermal therapy, especially due to 
its high absorption cross-sections in the near infrared (NIR) region [7,8]. These unique 
physio-chemical properties have enabled its wide application in the biomedical field, in-
cluding drug delivery, photothermal therapy, and tissue regeneration [9,10]. 
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Combining CS with GO could lead to a nanocomposite with unique functionality for 
a wide range of applications, particularly in the biomedical field. For instance, Barra et al. 
[11] developed electrically conductive CS/reduced GO flexible bio-nanocomposites for 
food packaging and biological applications. Hermenean et al. [12] fabricated a CS/GO 3D 
scaffold via pi-pi interaction, and the resulting composite has been proposed for bone re-
generation. Rana et al. [13] used CS to surface functionalize GO through chemical cross-
linking, with the in-vitro study showing the higher cell viability of the functionalized GO. 
Bao et al. [14] fabricated biocompatible CS-functionalized GO, which can be used as a 
nanocarrier for drug and gene delivery. Shamekhi et al. [15] prepared GO containing CS 
scaffolds for cartilage tissue engineering with enhanced physical and mechanical proper-
ties via cross-linking and incorporation of nanoparticles. Liu et al. [16] obtained 3D CS/GO 
scaffolds with aligned pores for tissue engineering with enhanced mechanical strength, 
shape-memory, cell scaffolding and protein adsorption ability. GO has also been used to 
improve the electrical conductivity of biomaterials in cardiac tissue engineering [17,18]. 
In several recent studies, silver nanoparticles (AgNPs) have been introduced to 
GO/CS system to endow the nanocomposite with additional antibacterial properties. For 
instance, Khawaja et al. prepared a GO/CS/AgNPs nanocomposite, where AgNPs were 
successfully prepared using green tea leaf extracts. The nanocomposite has been demon-
strated as a highly effective antibacterial agent against pathogenic strains [19]. Keshvar-
doostchokami et al. [20] prepared a similar GO/CS/AgNPs nanocomposite for antimicro-
bial applications, where NaOH was used as the reducing agent for synthesizing AgNPs. 
Jena et al. [21] also deployed a GO/CS/AgNPs nanocomposite as a coating with anticorro-
sion and antibacterial properties for marine applications. Despite the promising applica-
tions of the GO/CS/AgNPs nanocomposite system in the biomedical field, the photother-
mal function of GO and the potential of CS as a drug carrier within such a system have 
not been fully exploited. It is also worth noting that the traditional AgNPs synthesis meth-
ods present several limitations such as the use of harsh chemicals, elevated temperature, 
and/or a long processing time. 
The room temperature atmospheric pressure microplasma (RT-APM) process is a 
rapid, facile, and environmentally-friendly method that can be used to prepare AgNPs. 
During RT-APM, the solvated electrons and the rich plasma induced liquid chemistry 
contribute to the nucleation and growth of the AgNPs, and the rapid process (in minutes) 
eliminates the use of harsh/hazardous chemicals [22–25]. Previous study also shows that 
RT-APM synthesized CS/AgNPs nanocomposites have demonstrated tailored struc-
ture/properties as well as promising antibacterial activity against E. coli and S. aureus [26]. 
One interesting aspect worth further investigation is to introduce GO into the RT-APM 
synthesized CS/AgNPs, and fully exploit the functionality of each constituent material in 
this new hybrid CS/AgNPs/GO system for a wider range of functional applications. 
In this work, GO was introduced into RT-APM synthesized CS/AgNPs for the first 
time with the aim of producing a multifunctional chitosan/raspberry-like AgNPs/gra-
phene oxide (CS/RB-AgNPs/GO) composite system. The unique functionality of each con-
stituent material, i.e., the antimicrobial property of AgNPs, the pH responsive behavior 
of CS, and the photothermal converting property of GO, have been fully exploited for the 
first time for such a composite system. The novel multi-functionalities demonstrated by 
our CS/RB-AgNPs/GO composite system could enable its potential application in anti-
microbials, drug release platforms, and photothermal cancer therapy, among other areas. 
2. Materials and Methods 
2.1. Materials 
Chitosan (CS, low molecular weight 50,000–190,000 Da, 75–85% deacetylated), silver 
nitrate (AgNO3, ACS reagent, ≥99.0%), fluorescein sodium, methylene blue, and phos-
phate buffered saline (PBS) tablets (pH = 7.4) were purchased from Sigma-Aldrich (Gil-
lingham, UK). Graphene oxide (5 mg/mL aqueous solution, flake size: 0.5–5 µm, 1 atomic 
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layer at least 60%) was purchased from Graphene Laboratories, Inc (Calverton, NY, USA). 
Acetic acid (puriss, glacial, ≥99.9%) was obtained from Riedel-de Haën Sigma-Aldrich La-
borchemikalien GmbH (Heidenheim a. d. Brenz, Germany). Ultrapure water (>18.2 MΩ 
cm Millipore Milli-Q system) was used in all experiments. Helium gas was purchased 
from BOC, London, UK. Model drugs methylene blue (MB) and fluorescein (FL) were 
obtained from Sigma-Aldrich, UK. 
2.2. Fabrication CS/RB-AgNPs/GO Nanocomposite 
The room temperature atmospheric pressure microplasma process was used to syn-
thesize CS/AgNPs following the established procedure [25,26]. More specifically, as pur-
chased CS powder was dissolved in 2% (v/v) acetic acid and stirred for 24 h under room 
temperature to obtain a 2% (w/v) homogeneous solution, an appropriate amount of 
AgNO3 (4.0 mM) was added to the CS solution to obtain the precursor solution CS + 
AgNO3 mixture. The mixture was subject to RT-APM treatment and Scheme 1a gives the 
details of the RT-APM setup. A stainless-steel capillary cathode (0.25 mm inner diameter 
and 0.5 mm outer diameter) was placed ~1.5 mm above the solution surface, and a carbon 
rod (anode) was immersed in the liquid. Helium gas was passed through the cathode ca-
pillary at a flow rate of 25 SCCM. A constant current of 5 mA and a voltage of 0.7–1.0 kV 
were maintained during the plasma treatment. The RT-APM treatment was carried out 
for 10 min, and the samples were stirred during the treatment to obtain a well-mixed col-
loid (see Scheme 1b). The resulting sample is named CS/AgNPs. 
 
Scheme 1. (a) The schematic diagram of the atmospheric pressure microplasma setup for the preparation of CS/AgNPs, 
(b) CS + AgNO3 solution before and after RT-APM treatment, and (c) the preparation of CS/RB-AgNPs/GO nanocomposite 
using a freeze-drying process. 
The CS/RB-AgNPs/GO nanocomposite with 0, 0.5, and 1.5 wt% GO were prepared 
by adding the appropriate amount of GO into the RT-APM treated CS/AgNPs samples 
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followed by 30 min of sonication. All liquid samples were then transferred into a Teflon 
mold (with 9 mm diameter × 4 mm recess). The samples were frozen overnight at −35 °C, 
and then by freeze-dried (Lyotrap LTE, lte scientific ltd., Oldham, United Kingdom for 24 
h at −60 °C. Table 1 shows the composition and nomenclatures of the samples prepared in 
this study. 
Table 1. Nomenclatures of samples and their preparation methods. 
Sample Name GO wt% (vs. CS) 
AgNO3/CS Precursor Con-
centration RT-APM 
Pure CS None None No 
CS/AgNPs None 4.0 mM AgNO3 Yes 
CS/RB-AgNPs/GO-0.5 0.5% (w/w) 4.0 mM AgNO3 Yes 
CS/RB-AgNPs/GO-1.5 1.5% (w/w) 4.0 mM AgNO3 Yes 
2.3. Materials Characterization 
A Fourier transform infrared spectrometer (FTIR, Perkin Elmer Spectrum 100 ATR, 4 
cm−1 resolution and 36 scans per sample) was used to analyze the samples. Thermogravi-
metric analysis (TGA, TA Instruments SDT-Q600, New Castle, DE, USA) was carried out 
under nitrogen atmosphere over the temperature range 40–600 °C at 10 °C per min incre-
ments. The morphology of the cryo-fractured sample (gold sputtered) was observed by 
scanning electron microscopy (SEM, HITACHI FlexSEM 1000, Tokyo, Japan) with accel-
eration voltage in the range of 5–15 kV. Differential scanning calorimetry (DSC) was car-
ried out using a Perkin-Elmer DSC 6 instrument. The samples were first scanned at 20–
110 °C at 10 °C/min to remove water and eliminate thermal stress. The samples were then 
held at 110 °C for 10 min and cooled from 110 °C to 20 °C at a rate of 10 °C/min. The second 
scan was carried out from 20 °C to 380 °C at 10 °C/min. UV-vis spectroscopy (Cary Win 
UV, Santa Clara, CA, USA) was used to characterize drug release under pH 7.4 and pH 4, 
respectively. X-Ray Diffraction (XRD, PANalytical X’PERT ProMPD) was used to analyze 
the crystallinity of samples. Lloyd’s LRX Tensile Tester was used for the quasi-static me-
chanical testing in compression with a 50 N load cell, following ASTM D1621–10 [27] with 
specimen sizes (10 mm diameter, 5 mm height). Three measurements were taken for each 
sample [28]. 
2.4. Drug Releasing Tests 
Two model drugs fluorescein sodium (FL) and methyl blue (MB) were selected for 
single and dual drug release, following the established protocol [29]. To investigate the 
single drug release profile, FL loaded GO (1.5 mg FL per 100 mg GO), namely (GO-1.5)-
FL, or MB loaded CS/AgNPs (0.2 mg MB per mL of CS/AgNP colloid), namely 
(CS/AgNPs)-MB, was used to prepare the single drug laden nanocomposite, respectively. 
For dual drug release, both FL loaded GO and MB loaded CS/AgNPs were used. Three 
types of drug laden nanocomposites were prepared, namely, (CS/RB-AgNPs)-MB/GO-1.5, 
CS/RB-AgNPs/(GO-1.5)-FL, and (CS/RB-AgNPs)-MB/(GO-1.5)-FL. The drug release test 
was conducted in 10 mL PBS (pH 7.4 or 4.0, 37 °C). At different time intervals, 2.5 mL of 
test solution was analyzed using UV-vis spectrophotometer, and the remaining solution 
was topped up with fresh PBS. Three repeated measurements were performed for each 
sample and the cumulative release percentage of FL and MB was calculated following 
Equation (1): 
Cumulative drug release (%) = Mt/M0 ×100% (1)
where Mt is the amount of drug released at time t and M0 is the initial amount of drug 
loaded. 
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2.5. Antibacterial Tests 
The antibacterial properties of the nanocomposites were evaluated following estab-
lished method using gram-negative (E.coli) and gram-positive (S.aureus) strains [29,30]. 
100 µL of the overnight bacterial culture (1 × 108 CFU/mL) was spread on nutrient agar 
plates. The sample was then placed on the plates in triplicates, followed by incubation for 
24 h at 37 °C. After the incubation period, the inhibition length (i.e., the diameter of the 
inhibition zone surrounding the samples) was measured (n = 3), and the average value 
was used to determine anti-bacterial activity. More details regarding inhibition length 
measurement can be found in Figure S3 (Supplementary Materials). 
2.6. Statistical Analysis 
Statistical analysis was performed using SPSS software (version 22.0; IBM Corp., Ar-
monk, NY, USA), and the statistical significance was analyzed using one-way analysis of 
variance (ANOVA) followed by the LSD post hoc test. The relationships between different 
parameters were calculated using Pearson’s correlation test. Statistical significance was 
considered for p < 0.05, while high significance was p < 0.01. 
2.7. Photothermal Conversion Tests 
We followed the standard method for photothermal conversion measurements [31]. 
IR thermal camera (FORTIC 220RD PCBA, Shanghai, China) was used to capture the ther-
mal image of samples under near infrared (NIR) 808 nm laser irradiation with different 
laser powers (0.2, 0.4, 0.6, and 1.0 W), with a light window of 50.24 mm2. The temperature 
data were analyzed using AnalyzIR software (4.3.1.25). 
3. Results 
3.1. Materials Characterization 
Figure 1a shows the UV-vis spectra of all testing samples with their optical images 
shown in Figure 1b. In theory, GO should have an absorbance peak at around 200 nm due 
to the pi-pi* conjugation of C=C bonds [26]. However, this peak overlaps with the charac-
teristic peak of pure CS at 200–250 nm, and cannot be easily distinguished in the spectra 
of the CS/RB-AgNPs/GO composite samples. Figure 1b shows the change of solution color 
for different samples, where brown is indicative of the formation of AgNPs. The finding 
is consistent with previous studies on RT-APM synthesized AgNPs, where the presence 
of AgNPs is supported by the typical broad surface plasmon resonance (SPR) absorption 
peak at around 410 nm [25,26]. The TEM image in Figure 1c shows the morphology and 
size distribution of RB-AgNPs in CS/RB-AgNPs/GO-1.5 solution with an average size of 
73.69 nm (Figure 1d). It is worth noting from Figure S2 that in the RT-APM synthesized 
CS/AgNPs system (i.e., without GO), the AgNPs appear to be more spherical, have smaller 
particle sizes (mean particle size ~27.5 nm), and are better dispersed. Whereas for CS/RB-
AgNPs/GO-1.5, the AgNPs appear to be more agglomerated (raspberry-like) and have a 
larger particle size (mean particle size ~73.69 nm). It is known that GO has abundant neg-
atively charged oxygen-containing surface functional groups (e.g., –OH and –COOH), 
whereas CS is positively charged in aqueous solutions due to the protonation of the sur-
face amine group [29]. The strong electrostatic interaction between CS and GO have been 
reported by many researchers [32–34], and such interaction mechanisms have been de-
ployed for layer-by-layer self-assembled CS/GO coatings [29] and nanocapsules [35]. In 
this study, it is possible that the electrostatic interaction between CS and GO in our CS/RB-
AgNPs/GO-1.5 system contributed to the unique morphology formation of RB-AgNP, 
where multiple AgNPs tend to gather/agglomerate around the sites where CS and GO 
interact electrostatically, leading to the raspberry-like microstructure of AgNPs. 




Figure 1. (a) UV-vis spectra of all sample solutions, (b) photographs of all sample solutions, (c) 
TEM image of the CS/RB-AgNPs/GO-1.5, and (d) RB-AgNPs particle size distribution within the 
CS/RB-AgNPs/GO-1.5 sample. 
Figure 2a shows the optical images of pure CS and nanocomposites with different 
chemical compositions. The TGA results provide a better understanding of the thermal 
decomposition and thermal stability of pure chitosan and its composites. Figure 2b shows 
the DSC curves of pure CS, CS/AgNPs, and CS/RB-AgNPs/GO composites obtained from 
the second heating. The CS chain segmental mobility could be reflected by the glass tran-
sition temperature (Tg). The Tg of pure CS is 134.70 °C, and the broad baseline step is due 
to the rigidity of the CS molecular structure [36]. The presence of AgNPs increased the Tg 
of CS/AgNPs composites to 138.89 °C, whereas the presence of both GO and RB-AgNPs 
increased the Tg of CS/RB-AgNPs/GO-1.5 composites to 141.91 °C. The increase in Tg is 
ascribed to the interaction between CS chains and GO sheets and RB-AgNPs [37,38]. Such 
interaction may constrain the segmental motion of CS chains by hydrogen bonding and 
electrostatic interaction and hence increase its thermal stability [39]. The exothermic peak 
around 270–350 °C shown in Figure 2b and Table S1 indicates the thermal decomposition 
of composites, which is associated to the material weight loss seen in the TGA curves (Fig-
ure 2c). Our pure CS sample shows an initial decomposition of 270.16 °C. The decompo-
sition temperature depends on the polymer molecular weight and may be related to its 
hydrolytic depolymerization [40]. As shown in Figure 2c, all TGA curves have a similar 
decomposition trend, and the weight loss around 127.32 °C is attributed to the loss of 
water from the polymer. The presence of RB-AgNPs and GO delay the initial decomposi-
tion of the CS’s polymer chains, and lead to a higher residual mass than pure CS at 700 
°C. This can be explained by the decomposition hindering effect [41]. Figure 2d presents 
the FT-IR spectra of all samples. The characteristic bands of amide I and amide II groups 
are located at 1654 cm−1 and 1385 cm−1. The peaks at 1333 cm−1 and 1258 cm−1 belong to the 
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O-H bending vibration, and the anti-symmetrical stretching of the C-O-C bridge can be 
found at 1151 cm−1 [42,43]. The strong broad band at 3100–3650 cm−1 represents the char-
acteristic peak of N-H or O-H stretching vibration from CS, RB-AgNPs or GO [44]. The 
intensity of the N-H bending vibration peak at 1532 cm−1 decreases due to the interaction 
between AgNPs (or RB-AgNPs) and CS through hydrogen bonding [45]. 
 
Figure 2. (a) Optical images of pure CS and the typical nanocomposite samples, (b) DSC curves, 
(c) TGA curves obtained from the second heating, and (d) FT-IR spectra of pure CS, CS/AgNPs, 
and CS/RB-AgNPs/GO nanocomposites. 
3.2. Microstructural and Mechanical Analysis 
Further SEM analysis and mechanical testing (see Figure 3) shows the influence of 
AgNPs and GO on the composite microstructure and compressive modulus. RT-APM 
synthesized CS/AgNPs has reduced pore size but greater pore density when compared 
with pure CS, whereas CS/RB-AgNPs/GO-1.5, containing GO sheets with flake size 0.5–5 
µm, shows a more similar structure to pure CS. Figure 3 (d) shows the mean compressive 
elastic modulus of composite samples. The increased modulus for CS/AgNPs may be at-
tributable to hydrogen bond formation between AgNPs and the polymeric matrix, result-
ing in restricted motion of the polymer backbone chain [46]. When GO is introduced into 
the system, AgNPs (which are encapsulated by positively charged CS) may interact with 
the negatively charged GO flakes through electrostatic interaction [19]. This may lead to 
agglomeration of the AgNPs and/or GO (also see Figure S2), leading to the raspberry-like 
AgNP morphology. While well dispersed nanofillers have been reported to enhance the 
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composite mechanical properties, it is also widely recognized that agglomeration of nan-
ofiller materials can cause local stress concentration, thus deteriorating the mechanical 
properties of the resulting composites [47]. 
 
Figure 3. SEM images of (a) pure CS, (b) CS/AgNPs, and (c) CS/RB-AgNPs/GO-1.5. (d) Mean com-
pressive elastic modulus of the nanocomposite samples (n = 3 for each group). 
3.3. In-Vitro Drug Release Profiles 
FL and MB were selected as typical model drugs as their molecular weights are sim-
ilar to some anti-cancer, anti-inflammatory, and bone regeneration drugs [29]. The suc-
cessful loading of FL onto GO (GO-FL) can be confirmed by the UV-vis spectroscopy. 
Figure 4a shows the UV-vis spectra of GO, GO-FL, and the as-prepared FL solutions. The 
characteristic peaks of FL (238, 459 nm and 491 nm) were blue shifted to 231 nm, 448 nm, 
and 483 nm in the GO-FL sample. The characteristic peaks of MB at 292 nm and 663 nm 
remain unchanged after loading MB onto CS/AgNPs. These characteristic peaks were 
used to investigate the drug release behavior of MB (Figure 4b). 
For in-vitro drug release tests, we loaded MB onto CS/AgNPs or loaded FL onto GO 
to investigate the drug release profile of the different single drugs in the resulting CS/RB-
AgNPs/GO-1.5 composite system. Subsequently, we combined MB laden CS/AgNPs and 
FL laden GO to obtain the dual drug release system. Figure 5 presents the percentage of 
cumulative drug released under neutral (pH = 7.4) and acidic (pH = 4.0) conditions over 
240 h. For single drug release of MB (Figure 5a), a burst release was evident under pH 7.4 
in the first 10 h, followed by a more stabilized release of 70–80% after 40–50 h. Under pH 
4, however, the release rate was significantly accelerated and the drug release reached 100 
% from 80 h. In contrast, the single drug FL (Figure 5b) release shows a time lag behavior. 
Only 30% FL was released in the first 10 h under pH 7.4 and the cumulative release only 
increased slowly up to 45% towards the end of 240 h. The lower pH also significantly 
altered the release profile, which featured a continual increase in cumulative drug release 
at a much higher rate throughout the measurement period. It is worth mentioning that 
such pH responsive drug release behavior could be beneficial for on-demand cancer treat-
ment applications, as tumorous sites typically present a more acidic micro-environment 
[48,49]. Figure 5c,d shows the drug release profile of CS/RB-AgNPs/GO-1.5 when it acted 
a dual release system. It can be seen from Figure 5c that the addition of FL slowed down 
the MB release rate for both pH conditions as compared with the single drug (MB) release 
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system. In contrast, with the presence of MB, the FL release rate from CS/RB-AgNPs/GO-
1.5 increased slightly under both pH conditions. The complex interplay between different 
drugs and drug carriers will be further elucidated in Section 3.4. 
 
Figure 4. (a) UV-vis spectra of GO, GO-FL, and FL solutions, and (b) MB, CS/AgNPs-MB, CS-MB, and CS/AgNPs solu-
tions. Inset—photos showing colors of each as-prepared solution. 
 
Figure 5. (a) Single drug release profile of MB, (b) single drug release profile of FL, (c) dual drug release profile of MB, 
and (d) dual drug release profile of FL from CS/RB-AgNPs/GO−1.5. 
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Most GO based dual drug release systems reported in the literature deploy GO as the 
sole drug carrier for two types of drugs [50–53]. For instance, Tran et al. [50] developed a 
pH sensitive dual anticancer drug (doxorubicin and irinotecan)-loaded GO for cancer 
therapy. Pei et al. [53] synthesized a pH sensitive dual-drug-loaded PEGylated GO, where 
cisplatin and doxorubicin were loaded onto GO to facilitate combined cancer chemother-
apy. Both reports demonstrated faster drug release under acidic conditions, which has 
been attributed to the stronger hydrogen-bonding between the drugs’ functional group 
and GO’s surface functions under neutral conditions than under acidic conditions. In the 
present study, both CS and GO were deployed as drug carriers. The single drug and dual 
drug release profiles shown here follow a similar trend to those previously reported in 
multi-drug laden coating systems consisting of layer-by-layer assembled CS and GO [29]. 
The greater release rate of both drugs under lower pH can be mostly attributed to the 
swelling of the chitosan matrix under acidic conditions due to the protonation of its 
amino/imine groups [54]. The swelling of CS results in a more porous composite structure, 
and therefore a less hindered drug elution pathway. However, in the present study, the 
levels of cumulative release in the single/dual drug release models are significantly dif-
ferent from the previously reported coating system. This could be attributed to the vastly 
different composite microstructures adopted in the two studies, which may significantly 
affect the interfacial interaction between CS and GO and the potential drug elution path-
ways. 
3.4. In-Vitro Drug Release Kinetic Model 
In order to obtain a suitable drug release model that best describes the drug release 
profile, several kinetic models have been considered for the drug release systems involved 
in this study. These include zero order (cumulative percent drug released versus time), 
first order (log cumulative percent drug retained versus time), Higuchi (cumulative per-
cent drug released versus√time), and Korsmeyer–Peppas (log cumulative percent drug 
released versus log time). Curve fitting was carried out following [55], and the data can 
be found in Figures S4 and S5. The modelling accuracy was evaluated by comparing the 
coefficient of determination (R2) values. In the Korsmeyer–Peppas (Fickian diffusion) 
model, the mechanism of drug release was indicated by the value of the release exponent 
N [56,57]. Porous structures typically exhibit N < 0.45, and diffusion occurs through water-
filled pores and the polymer layer due to the swollen matrix [58,59]. 
The drug release kinetic analysis results from Table S2 suggest that the Korsmeyer–
Peppas model (which shows the highest overall R2 values) best describes the predominant 
release mechanism for both single and dual drug systems (Figure 6). The porous structure 
of the composite was corroborated by the value of release exponent N < 0.45. When fitting 
the drug release curves based on the Korsemeyer–Peppas model, [60,61], the cumulative 
amount of drug release (Mt) could be described by equation (2): 
Mt = ktN (2)
where N was the release exponent in the Korsmeyer–Peppas model, indicative of the drug 
release mechanism, t was the time elapsed, and k was defined by equation (3): 
k = A√(2Cinit DCs)) (3)
where A was the cross-sectional area of the sample, Cinit was the initial concentration of 
the drug (MB = 0.2 mg/mL and FL = 1.5 wt%), Cs was the solubility (70 mg/mL for MB and 
500 mg/mL for FL), and D was the diffusion coefficient of the drug (0.42×10−5 cm2/s for 
pristine FL and 0.79 × 10−5 cm2/s for pristine MB) [62]. 




Figure 6. Fitting of single and dual drug release curves to the Korsmeyer–Peppas model (solid lines). 
The true diffusion coefficients (DK) of each system following the Korsemeyer–Peppas 
model were obtained through further optimization towards the objective function. The 
curve fitting values for DK, N and, the corresponding R2 values can be found in Table 2. 
Table 2. The kinetic parameters in Korsmeyer–Peppas models. 
Sample Code 
Korsmeyer–Peppas Model Fit All 
Range 
 DK (×10−5 cm2s−1) N R2 
(CS/RB-AgNPs)-MB/GO-1.5 pH = 7.4 1.573 0.098 0.983 
(CS/RB-AgNPs)-MB/GO-1.5 pH = 4.0 1.949 0.121 0.915 
CS/RB-AgNPs/(GO-1.5)-FL pH = 7.4 0.0231 0.155 0.981 
CS/RB-AgNPs/(GO-1.5)-FL pH = 4.0 0.0168 0.347 0.986 
(CS/RB-AgNPs)-MB/(GO-1.5)-FL pH = 7.4 MB 0.572 0.126 0.969 
(CS/RB-AgNPs)-MB/(GO-1.5)-FL pH = 4.0 MB 0.811 0.142 0.936 
(CS/RB-AgNPs)-MB/(GO-1.5)-FL pH = 7.4 FL 0.0437 0.161 0.995 
(CS/RB-AgNPs)-MB/(GO-1.5)-FL pH = 4.0 FL 0.0596 0.254 0.968 
For the dual drug system, the true diffusion coefficient of MB and FL is different from 
the ideal diffusion coefficient due to the potential host-guest and guest-guest interactions 
[63] between GO, MB, and FL (see Figure 7). In our drug laden composites, FL was loaded 
onto GO via weak pi-pi interaction, which can be described as a weak host-guest (GO-FL) 
interaction. When MB was introduced into the system, the stronger ionic interaction be-
tween MB and GO (host-guest (GO-MB)) drove the replacement of the loosely adsorbed 
FL with MB to form a more stable structure, leading to a slower MB release but a greater 
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FL release. In addition, the repulsive force between the negatively charged functional 
groups on FL and GO accelerate the desorption process of FL from GO sheet surface. 
 
Figure 7. The interaction mechanism of GO, MB, and FL. 
3.5. Antibacterial Ability 
The diameters of the inhibition zones (inhibition length) were used to evaluate the 
nanocomposite’s antibacterial ability against E. coli and S. aureus (see Figure 8). It can be 
seen that pure CS exhibits no visible antibacterial ability. In contrast, samples containing 
AgNPs and RB-AgNPs showed significantly enhanced antibacterial performance. The 
presence of Ag can generate reactive oxygen species (ROS) when in contact with the bac-
terial strains, and these ROS could destabilize the bacteria plasma membrane potential, 
deplete the levels of intracellular adenosine triphosphate, and eventually lead to the death 
of bacterial cells [64]. The presence of GO (particularly at 1.5%w/w), can further enhance 
antibacterial ability as compared to the CS/AgNPs sample. This could be attributed to the 
GO’s ability to cause oxidative pressure [65] or bacterial cell membrane damage [66]. 
 
Figure 8. Inhibition lengths of different samples against (a) E. coli, and (b) S. aureus of different samples (n = 3), *** p < 
0.001, ** p < 0.01, * p < 0.05 vs. pure chitosan. 
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3.6. Photothermal Conversion 
All samples were immersed in PBS solution, and their photothermal conversion be-
havior under 808 nm laser irradiation were examined, with PBS solution being the control. 
Figure 9a,b show that under 1 W laser irradiation, samples containing no GO exhibited 
no photothermal conversion effect. For CS/RB-AgNPs/GO composites, the sample con-
taining greater GO content demonstrated greater photothermal conversion efficiency. Fig-
ure 9c shows that by manipulating the laser power, the temperature profile of the selected 
sample (CS/RB-AgNPs/GO-1.5) can be fine-tuned. When 2 W power was used, the sam-
ples were heated to 45 °C within 100 s, which is within the therapeutic window for pho-
tothermal therapy applications. Figure 9d further confirms the composite samples have 
sufficient photothermal conversion stability during the cyclic heating/cooling tests. The 
photothermal performance of CS/RB-AgNPs/GO-1.5 did not deteriorate. This is consistent 
with other GO (or graphene) containing composite systems reported in the literature with 
similar photothermal conversion functions [7,29], demonstrating the strong promise of 
nanographene materials in on-demand photothermal applications. 
 
Figure 9. Photothermal conversion of all testing samples (a) Temperature profile and (b) IR thermal images of different 
samples under 808 nm laser irradiation (1.0 W) from 0 to 3 min. (c) Temperature profile of CS/RB-AgNPs/GO-1.5 irradiated 
by laser with different powers. (d) Photothermal conversion stability of CS/RB-AgNPs/GO-1.5 irradiated by 808 nm laser 
(power: 1.0, 1.4, and 2.0 W). The sample was irradiated for 3 min and then cooled down to 23 °C with three repeating 
cycles. 
  




In this study, we fabricated a CS/RB-AgNPs/GO hybrid nanocomposite by incorpo-
rating GO into RT-APM synthesized CS/AgNPs. The resulting nanocomposite has then 
been characterized as potentially having several functional applications including multi-
drug release, as an anti-microbial, and photothermal conversion. The drug loading/release 
behavior and the underlying mechanisms have been studied in detail using both single 
drug and dual drug models. Our composite system demonstrated pH-sensitive release, 
and the drug release profile can best be described by the Korsmeyer–Peppas model. The 
nanocomposite also demonstrated significant anti-microbial properties against E.coli and 
S.aureus bacteria strains, as well as photothermal conversion properties. These promising 
functionalities may lead to the potential application of our nanocomposite in multiple 
fields, such as multi-therapeutic platforms for the treatment of certain cancers, anti-mi-
crobial membranes/coatings, water treatment, and many others. 
Supplementary Materials: The following are available online at www.mdpi.com/1996-
1944/14/9/2351/s1. Table S1: Effect of AgNPs and GO addition on the thermal properties of pure CS, 
CS/AgNPs and CS/AgNPs/GO scaffold; Table S2: The kinetic parameters for different drug release 
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